CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its
PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors.
Pacira BioSciences (PCRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares were flat post-release as investors weighed the performance. The company highlighted progress in its non-opioid pain portfolio and gene therapy pipeline.
PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors.
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability, steady growth, and reasonable financial health, making it a candidate for value investors.
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.
